TALS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 okt 2023 @ 22:00):

Stats
Dagens volum	303 484
Gjennomsnittsvolum	142 922
Markedsverdi	116.44M
EPS	$-0.460 ( 2023-11-08 )
Last Dividend	$1.512 ( 2023-10-19 )
Next Dividend	$0 ( N/A )
P/E	-1.563
ATR14	$0.122 (4.49%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-13	Siegall Clay B	Buy	20 000	Stock Option (Right to Buy)
2023-12-13	Siegall Clay B	Buy	0
2023-11-17	Kulkarni Sandeep Chidambar	Buy	4 000	Common Stock
2023-11-17	Thiara Parvinder	Buy	1 000	Common Stock
2023-10-27	Castelein Caley	Buy	15 800	Common Stock

INSIDER POWER
83.81
Last 89 transactions
Buy: 5 796 448 \| Sell: 603 108

Volum Korrelasjon

Lang: 0.00 (neutral)

Kort: -0.17 (neutral)

Signal:(46.625) Neutral

Talaris Therapeutics, Korrelasjon

10 Mest positive korrelasjoner
MRNS	0.86
NPCE	0.842
ALR	0.818
SMED	0.817
EPZM	0.815
BIS	0.808
THRY	0.807
LTRY	0.807
CNCE	0.805
LVO	0.802

10 Mest negative korrelasjoner
WTBA	-0.867
EGAN	-0.854
ABST	-0.853
CRNT	-0.851
BNIXU	-0.85
PIXY	-0.834
CNDT	-0.832
FREQ	-0.823
VWE	-0.817
UPC	-0.813

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Talaris Therapeutics, Korrelasjon - Valuta/Råvare

0.05
( neutral )

-0.24
( neutral )

-0.33
( neutral )

-0.11
( neutral )

-0.78
( moderate negative )

0.00
( neutral )

Talaris Therapeutics, Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-16.66

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-16.66

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.26

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.070

Financial Reports:

No articles found.

Talaris Therapeutics, Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$1.512 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Talaris Therapeutics, Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.512	2023-10-19
Last Dividend	$1.512	2023-10-19
Next Dividend	$0	N/A
Payout Date	2023-10-20
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$1.512	--
Avg. Dividend % Per Year	46.23%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-30)

$3.02 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$1.512	138.70%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.382	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.364	1.500	-5.16	-7.74	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	18.64	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	18.14	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	8.28	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00420	-1.500	9.93	-10.00	[0 - 0.6]
interestCoverageTTM	-17.91	1.000	-7.75	-7.75	[3 - 30]
operatingCashFlowPerShareTTM	-12.28	2.00	-4.09	-8.19	[0 - 30]
freeCashFlowPerShareTTM	-12.47	2.00	-6.24	-10.00	[0 - 20]
debtEquityRatioTTM	0.00444	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-82.75	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-1.667

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.202	1.000	-0.121	0	[1 - 100]
returnOnEquityTTM	-0.364	2.50	-3.32	-7.74	[0.1 - 1.5]
freeCashFlowPerShareTTM	-12.47	2.00	-4.16	-10.00	[0 - 30]
dividendYielPercentageTTM	55.58	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-12.28	2.00	-4.09	-8.19	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.00392	1.500	-3.36	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-2.25

Talaris Therapeutics,

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.